Journey Medical (DERM) to Release Earnings on Thursday

Journey Medical (NASDAQ:DERM) will likely be posting its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Journey Medical to post earnings of ($0.22) per share for the quarter.

Journey Medical Price Performance

Shares of NASDAQ:DERM opened at $5.33 on Wednesday. The business’s 50 day simple moving average is $4.74 and its 200-day simple moving average is $5.10. The firm has a market capitalization of $111.34 million, a price-to-earnings ratio of -5.67 and a beta of 0.97. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. Journey Medical has a 12 month low of $2.85 and a 12 month high of $6.89.

Insider Transactions at Journey Medical

In related news, CEO Claude Maraoui sold 18,147 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total value of $93,094.11. Following the sale, the chief executive officer now owns 2,092,874 shares of the company’s stock, valued at approximately $10,736,443.62. This represents a 0.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 105,831 shares of company stock valued at $536,622 in the last quarter. 13.16% of the stock is currently owned by corporate insiders.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.